C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies

Leukemia and Lymphoma

Volumn 45, Issue 11, 2004, Pages 2281-2289

  Kraj, Maria ^a   Pogłód, Ryszard ^a   Kopeć Szlezak, Joanna ^a   Sokołowska, Urszula ^a   Woźniak, Jolanta ^a   Kruk, Barbara ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

C kit; CD117; MGUS; Multiple myeloma; Plasma cell leukemia; Plasma cells

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CD38 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; IMMUNOGLOBULIN CLASS; LACTATE DEHYDROGENASE; MELPHALAN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; TUMOR MARKER; VINCRISTINE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING SITE; BONE MARROW; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; COMPUTER PROGRAM; CONTROLLED STUDY; DEVICE; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; IMMUNOREACTIVITY; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAINING; SURVIVAL TIME;

ADP-RIBOSYL CYCLASE; AGED; ANTIGENS; ANTIGENS, CD; ANTIGENS, CD38; BINDING SITES; BIOPSY; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PLASMACYTIC; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-KIT; REMISSION INDUCTION; SYNDECAN-1; SYNDECANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 8644278874     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190412331283279     Document Type: Article

References (49)

1. Linnekin, D. (1999) "Early signaling pathways activated by c-KIT in hematopoietic cells", International Journal of Biochemistry and Cell Biology, 31, 1053-1074.
2. Smith, M.A., Pallister, C.J. and Smith, J.G. (2001) "Stem cell factor: biology and relevance to clinical practice", Acta Haematologica, 105, 143-150.
3. Ashman, L.K., Cambareri, A.C., To, L.B., Levinsky, R.J. and Juttner, C.A. (1991) "Expression of the YB5. B8 antigen (c-kit proto-oncogen product) in normal human bone marrow", Blood, 78 30-37.
4. Ogawa, M., Matsuzaki, Y., Nishikawa, S., Hayashi, S.I., Kunisada, T., Sudo, T., et al. (1991) "Expression and function of c-kit in hemopoietic progenitor cells", Journal of Experimental Medicine, 174, 63-68.
5. Schwartz, S., Heinecke, A., Zimmerman, M., Creutzig, U., Schoch, C., Harbott, J., et al. (1999) "Expression of the e-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML) including cytogenetically good-risk AML and lacks prognostic significance", Leukemia and Lymphoma, 34, 85-94.
6. Bayer-Garner, I.B., Schwartz, M.R., Lin, P. and Smoller, B.R. (2003) "CD117, but not lysozyme, is positive in cutaneous plasmacytoma", Archives of Pathology and Laboratory Medicine, 127, 1596-1598.
7. + anaplastic large cell lymphomas", Blood, 83, 785-792.
8. Bravo, P., Agustin, B.D., Bellas, C., Gonzales, D., Camara, C., Fuertes, I.F., et al. (2000) "Expression of high amounts of the CD117 molecule in a case of B-cell non Hodgkin's lymphoma carrying the t(14:18) translocation", American Journal of Hematology, 63 226-229.
9. Di Paola, R.S., Kuczyński, W.I., Onodera, K., Ratajczak, M.Z., Hijiya, N., Moore, J., et al. (1997) "Evidence for a functional c-kit receptor in melanoma, breast cancer and lung carcinoma cells" Cancer Gene Therapy, 4, 176-182.
10. Krystal, G.W., Honsawek, S., Litz, J. and Buchdunger, E. (2000) "The selective tyrosine kinase inhibitor STI 571 inhibits small lung cell cancer growth", Clinical Cancer Research, 6, 3319-3326.
11. Naraghi, S., Khoshyomn, S., De Mattia J.A. and Vane D.W. (2000) "Receptor tyrosine kinase inhibition suppresses growth of pediatric renal tumor cells in vitro", Journal of Pediatric Surgery 35, 884-890.
12. Wang, W.L., Healy, M.E., Sattler, M., Verma, S., Maulik, G., Stiles, C.D., et al. (2000) "Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571", Oncogene, 19, 3521-3528.
13. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., et al. (1999) "C-KIT proto-oncogene exon 8 inframe deletion plus insertion mutations in acute myeloid leukemia" , British Journal of Haematology, 105, 894-900.
14. Lemoli, R.M., Fortuna, A., Grande, A., Gamberi, B., Bonsi, L., Fogli, M., et al. (1994) "Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells", British Journal of Haematology, 88, 760-769.
15. Lemoli, R.M. and Fortuna, A. (1996) "C-kit ligand (SCF) in human multiple myeloma cells", Leukemia and Lymphoma, 20, 457-467.
16. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia", British Journal of Haematology, 106, 669-681.
17. Escribano, L., Ocqueteau, M., Almeida, J., Orfao, A. and San Miguel, J.F. (1998) "Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis", Leukemia and Lymphoma, 30, 459-466.
18. Lin, B., Podar, K., Gupta, D., Tai, Y.T., Li, S., Weller, E., et al. (2003) "The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment", Cancer Research, 62, 5019-5026.
19. Pogłód, R., Kraj, M., Kopeć-Szlezak, J. and Kruk, B. (2001) Expression of the CD117 (c-kit) on myelomatous plasma cells. 1. In Proceedings of the "European Federation of Immunological Societies-EFIS 2000" (Poznań 2000), edited by A. Mackiewicz. Pp. 433-437. Bologna (Italy): Monduzzi Editore. 2. Immunology Letters, 73, 123.
20. Capdeville, R., Buchdunger, E., Zimmermann, J. and Matter, A. (2002) "Glivec (STI 571, imatinib), a rationally developed, targeted anticancer drug", Nature Reviews. Drug Discovery, 1, 493-502.
21. Talpaz, M., Silver, R.T., Druker, J.B., Goldman, J.B., Gambacorti-Passerini, C., et al. (2002) "Imatinib induces durable hematologic and cytogenetic response in patients with accelerated phase of chronic myeloid leukemia: results of a phase 2 study", Blood, 1928-1937.
22. Joensuu, H., Roberts, P.J., Sarlomo-Rikała, M., Anderson, L.C., Tervahartiała, P., Tuveson, D., et al. (2001) " Effect of the tyrosine inhibitor STI 571 in a patient with a metastatic gastrointestinal, stromal tumor", New England Journal of Medicine, 344, 1052-1056.
23. Dispenzieri, A., Witzig, T.E., Lacy, M.Q., Rajkumar, S.V., Geyer, S.M., Kimlinger, T.,et al. (2002) "A phase II trial of Gleevec TM in patients with refractory/relapsed myeloma", Blood, 100(11), 814a, abstract # 3217.
24. Kraj, M., Pogłód, R., Kopeć-Szlezak, J., Sokołowska, U., Kruk, B. and Woźniak, J. (2002) " Expression of the CD117 antigen (c-kit) on plasma cells in monoclonal gammopathies.", 1. International Journal of Hematology, 76(suppl. 1), 24.
25. Kraj, M., Pogłód, R., Kopeć-Szlezak, J., Sokołowska, U., Kruk, B. and Woźniak, J. 2. The Hematology Journal, 2003; 4(suppl. 1), S113.
26. Kraj, M., Pogłód, R., Kopeć-Szlezak, J., Sokolowska, U., Woźniak, J. and Kruk, B. (2002) "Expression of the CD117 antigen (c-kit) on myelomatous plasma cells and its clinical implications. 1", Blood, 100(11Pt2), 367b.
27. Kraj, M., Pogłód, R., Kopeć-Szlezak, J., Sokolowska, U., Woźniak, J. and Kruk, B. 2. The Hematology Journal, 4 suppl. 2), 153.
28. Kraj, M., Pogłód, R., Kopeć-Szlezak, J., Sokolowska, U., Woźniak, J. and Kruk, 3. Immunology Letters, 2003; 87 1-3), 209.
29. Durie, B.G.M. and Salmon, S.E. (1975) "A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival", Cancer, 36, 842-854.
30. Miwa, H., Mizutani, M., Mahmud, N., Yamaguchi, M., Takahashi, T., Shikami, M., et al. (1998) "Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin", Leukemia, 12, 443-451.
31. Davis, K.A., Abrams, B., Hoffman, R.A. and Bishop, J.E. (1996) "Quantitation and valence of antibodies bound to cells", Cytometry, AC150(suppl 8), 150.
32. Cascavilla, N., Musto, P., D'Arena, G., Melillo, L., Carella, A.M., Petrilli, M.P., et al. (1998) "CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype", Haematologica, 83, 392-397.
33. Woźniak, J. and Kopeć-Szlezak, J. (2004) "C-Kit receptor (CD117) expression on myeloblasts and white blood cell (WBC) counts in acute myeloid leukemia (AML)", Cytometry, 58B, 9-16.
34. Scolnic, M.P., Morilla, R., de Bracco, M.M., Catovsky, D. and Matutes, E. (2002) "CD34 and CD117 overexpression in AML may be valuable to detect minimal residual disease", Leukemia Research, 26, 615-619.
35. Hans, C.P., Finn, W.G., Singleton, T.P., Schnitzer, B. and Ross, C.W. (2002) "Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia", American Journal of Clinical Pathology 117, 301-305.
36. Khalidi, H.S., Brynes, R.K., Medeiros, L.J., Chang, K.L., Slovak, M.L., Snyder, D.S., et al. (1998) "The immuynophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in " lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings", Modern Pathology, 11, 1211-1221.
37. Ocqueteau, M., Orfan, A., Garcia-Sanz, R., Almeida, J., Gonzales, M. and San Miguel, J.F. (1996) "Expression of CD117 (c-kit) on normal and myelomatous plasma cells", British Journal of Haematology 95, 489-493.
38. Almeida, J., Orfao, A., Ocqueteau, M., Mateo, G., Corral, M.D., Bladè, J., et al. (1999) "High sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma", British Journal of Haematology 107, 121-131.
39. Lugli, A., Went, P., Khanlari, B., Nikolova, Z. and Dirnhofer S. (2004) "Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment", Virchow's Archiv., 444, 264-268.
40. Heinrich, M.C., Blanke, C.D., Druker, B.J. and Corless, C.L. (2002) "Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies", Journal of Clincal Oncology, 20, 1692-1703.
41. Heinrich, P.C., Griffith, D.J., Druker, B.J., Wait, C.L., Ott, K.A. and Ziegler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", Blood, 96, 925-932.
42. Inokouchi, K., Yamaguchi, H., Tarusawa, M., Futaki, M., Hanawa, H., Tanosaki, S., et al. (2002) "Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia-potential clinical significance", Leukemia, 16, 170-177.
43. Roumiantsev, S., Shah, N.P., Gorre, M.E., Nicoll, J., Brasher, B.B., Sawyers, C.L., et al. (2002) "Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop", Proceedings of the National Academy of Sciences, 99, 10700-10705.
44. Pierce, A., Spooncer, E., Ainsworth, S. and Whetton, A.D. (2002) "BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor", Oncogene, 21, 3068-3075.
45. Buchdunger, E., Cioffi, C.L., Law, N., Stover, D., Ohno-Jones, S., Druker, B.J., et al. (2000) " Abl-protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors". Journal of Pharmacology and Experimental Therapy, 295, 139-145.
46. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarckson, B. and Kuriyan, Y. (2000) "Structural mechanism for STI-571 inhibition of abelson tyrosine kinase", Science, 289, 1938-1942.
47. Pandiella, A., Carvajal-Vergara, X., Tabera, S., Mateo, G., Gutièrrez, N. and San Miguel, J.F. (2003) "Imatinib mesylate (STI 571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents", British Journal of Haematology 123, 858-868.
48. Hallek, M., Bergsagel, L. and Anderson, K.C. (1998) "Multiple myeloma: increasing evidence for a multistep transformation process", Blood, 91, 3-21.
49. San Miguel, J.F., Almeida, J., Ocqueteau, M. and Orfao, A. (1997) "Detection of two subpopulations of plasma cells in MGUS patients. Utility in the differential diagnosis with multiple myeloma", Blood, 88(Suppl 1), 2550 (Abstract).